This
level-4 vital article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
This article contains a translation of Farmacocinética from es.wikipedia. |
Extended content
|
---|
This is an important topic that deserces an article of its own. However, copying the abstradt of a review article verbatim in Wikipedia is against the rules (copyright violation) and not useful, because these docoments are too long and too technical. The editor is welcome to write a short encyclopedic excerpt, taking into account other sources like WHO, NIH etc. Andreas 17:13, 9 January 2006 (UTC) I have been given the assignment of giving a brief lecture at my church on this very topic. I will web-research the topic and write my findings to this article. As a retired, but still licensed registered nurse, I have limited access to hospital medical libraries. I will also make my best effort at including references and links. User:W8IMP 0837, 15 January 2007]] (UTC) Why is this article titled "Pharmacokinetics (section), when there is another article, not a "talk" section devoted to this topic. I would gladly re-title the article as "Drug-drug and drug-herbal interactions", as soon as I have more data, and someone tells me to change the title. User:W8IMP 08:51, 15 January 2007]] (UTC) |
The constant which relates the exponent of decay (k) and half-life is easily determined by first principles from the equation for exponential decay. Mentioning circuit analysis seems totally crazy to me; no pharmacokineticist would know anything about circuits or ever need to. If this is important then I think that the maths only should be mentioned. ben 06:50, 23 May 2006 (UTC)
Shouldn't there be something here about two (or more) compartment models, also non compartmental models? Let me hasten to add, I'm not the person to write it ... Daen 15:22, 25 September 2006 (UTC)
Actually, there are PK model assumptions made for the typical implementation of numerical integration, A.K.A. noncompartmental methods. Those assumptions become important when they are incorrect, which may actually be almost all of the time. Those assumptions commonly, but not always, include (1) that between samples of a monotonically decreasing blood concentration (i.e., a washout model of plasma or whole blood depending on the drug's hydrophilicity and lipophilicity), that the path of concentration is exponential. (2) That one can extrapolate exponentials to earlier times than the first sample time without error. (3) That the last and one or two prior samples can be used to extrapolate the AUC to infinity implying (3a) that the half-life is terminal at that time and (3b) that half-lives only arise from exponential functions. Granted, there are other ways of doing numerical integration, and the selection of extrapolating functions is not trivial. Let us review these assumptions. Ad (1) and (2), there is no evidence to that effect, and early concentration of a renal filtered non metabolized drug has been shown to be more a linear concentration and logarithm of time function than a logarithm of concentration linear time function [1]. Indeed, the former implies an initial zero volume of drug and the later implies an unrealistic instant mixing in an appreciable volume (see below). The dearth of testing on this subject appalls me. Ad (3a), the half-life for the last samples is typically not terminal. Indeed, the terminal function may occur very late in time and may be a power function [2], what the terminal function does not appear to be is an exponential [3], which reference also offers an explanation of drug volumes in time. I welcome comments on this, and have not altered the main text due to a conflict of interest on my part. I need other minds to review this. CarlWesolowski ( talk) 16:08, 23 August 2016 (UTC).
BTW, there are multiple circumstances in which compartmental models are not "the best" at anything. Rather than give a whole bunch of references here regarding the need to correct one compartmental clearances by 15% or so, the superiority of other methods like constant infusion and saturated systems for measuring clearance, adaptive gamma variate fitting for bolus experiment clearances, Michaelis-Menten for saturable receptor clearances and so forth, I just changed the text to be more honest, i.e., from best to most frequently used. Also, there are broken links in the text some of which I have fixed, HELP!!! This isn't my article, so would someone else take care of it, too, please? And, if you don't agree with my (minor) changes, do let's talk, please. CarlWesolowski ( talk) 20:20, 9 February 2017 (UTC)
It may be more useful to refer to Enzyme kinetics. At the very least, there should be a reference to it somewhere in the article. 136.165.191.251 ( talk) 16:07, 27 April 2009 (UTC)
References
Variable volume pharmacokinetic models is now linked to this article. Linking back is a consideration, so is thinking about it. Talk to me. CarlWesolowski ( talk) 14:20, 23 August 2016 (UTC) CarlWesolowski ( talk) 03:44, 9 September 2016 (UTC) No one talked to me. The linking article was an orphan so that linking to it was needed. And for completeness, it should be listed anyway. CarlWesolowski ( talk) 21:53, 17 November 2016 (UTC)
Who "invented" the "Pharmacokinetics"? —Preceding unsigned comment added by 217.86.119.8 ( talk) 21:22, 3 October 2006 (UTC)
References
Would it be useful to have a list of the standard PK parameters, with some brief explanation? Examples: Cmax, Tmax, AUC, etc. —Preceding unsigned comment added by 216.158.41.81 ( talk) 18:35, 27 June 2007 (UTC)
It would be helpful to me! I would definitely read that section carefully. Mlbish ( talk) 21:32, 21 February 2008 (UTC)
References
Several drug properties can often influence the pharmacokinetics of many drugs.
The partition or distribution coefficient (KD) is the ratio of concentrations of a compound in the two phases of a mixture of two immiscible solvents at equilibrium. [1] It can influence the ADME properties (Absorption, Distribution, Metabolism, and Excretion) of the drug. When orally administered drugs are absorbed they must first pass through lipid bilayers in the intestinal epithelium (a process known as transcellular transport). For efficient transport the drug must be hydrophobic enough to partition into the lipid bilayer but not so hydrophobic that once it is in the bilayer it will not partition out again. [2] The partition coefficient is dependent on the hydrophobic or hydrophilic properties of the drug.
References
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
Drug transporters are transmembrane proteins on the surface of cells and are responsible for facilitating or hindering the intracellular and paracellular transport of nutrients and other substances. Some known drug transporters include Breast Cancer Resistance Protein (BCRP, also known as ABCG2) and human intestinal peptide transporter (hPepT1). BCRP is a type of ATP-binding cassette transporter that can decrease the efficacy of chemotherapeutic agents in breast cancer by exporting agents out of the tumor cells, thus making them resistant to chemotherapy. Valacyclovir uses the hPepT1 transporter to increase the intestinal absorption of valacyclovir compared to acyclovir. Drug transporters can increase or decrease the absorption of drugs into the body as well as limit or facilitate the exposure of certain organs.
Perfusion or flow of blood to different organs, affects rate of presentation of drugs to different parts of the body and often affects the pharmacokinetics of many drugs. While the partition coefficient can affect the distribution of drugs from the blood stream to the organs, perfusion affects how fast a drug is presented to the organs. Different organs receive a vast supply of drugs while others receive minor amounts. For example, the kidneys receive vast quantities of blood, especially considering the relatively small size of the kidneys. Adipose tissue, on the other hand, receives a minor supply blood. Organs with a rich blood supply would be presented drug at a higher rate than organs with a lower blood supply.
Biophys ( talk) 01:56, 5 September 2008 (UTC)
Hello. I am a member of WikiProject Pharmacology, a Wikipedia wide project that maintains and improves articles that fall under the scope of pharmacology. Since your article has fallen under our scope, I have placed the correct template(s) on this talk page for verification. Upon review of the article, I'd like to make a few points, as shown:
I'm glad this article could fall within our scope, and I hope to see it grow large! Many thanks! Renaissancee (talk) 02:21, 3 June 2009 (UTC)
This article is quite poor to be in the English version of Wikipedia; I compared it with other versions like the spanish one, and I noticed there is an important lack of information here. An improvement of this article should be done. —Preceding unsigned comment added by 83.44.20.68 ( talk • contribs) 01:20, 20 September 2009 (UTC)
I have added a review of the development of the Plateau Principle in pharmacokinetics and the wide applicability of the mathematical model to other areas in biological sciences. It would be very helpful to obtain an expert review of this new entry. Please provide comments in the talk section of Plateau Principleand delete this section when a review has been done. Many thanks. Jhargrov ( talk) 14:03, 10 October 2009 (UTC)James Hargrove Jhargrov ( talk) 14:03, 10 October 2009 (UTC)
It's been a while since I've dealt with topics in pharmacokinetics. Is "liberation" a new and recognized stage of drug kinetics? If so, please provide citation. -- Bobthefish2 ( talk) 04:53, 7 August 2011 (UTC)
{{
cite book}}
: Unknown parameter |coauthors=
ignored (|author=
suggested) (
help) Some points to note: Liberation is synonymous to drug release (which is by far more commonly used) and is further divided into desintegration and dissolution. There is a wealth of information available. Earlier references on LADME (from the 1970ies) are in German – which is not surprising, since a lot of work in the field at that time was done in German-speaking countries (Germany, Switzerland, Austria; the term pharmacokinetics was translated from Pharmakokinetik – a neologism introduced by
Friedrich Hartmut Dost in 1953). I would keep the statement about LADME in the article as it is – until somebody (te-heh) advances PK to a better shape. ;-)
Alfie
↑↓
© 13:03, 18 August 2011 (UTC)Following copied from User_talk:Boghog#Alpha.2FBeta_phase_of_i.v.:
Hi Boghog, I saw your new section and I think it's well-written. One additional thing that'd be helpful is to include an example chart of concentration vs. time with arrows pointing to the phase where passive diffusion dominates and the phase where elimination dominates (By the way, do you mean elimination as in "excretion" or elimination as in "metabolism" + "excretion"? Some pharmacologists use the term "elimination" in the same way as "excretion"). -- Bobthefish2 ( talk) 18:13, 26 August 2011 (UTC)
End of insert Alfie ↑↓ © 00:07, 1 September 2011 (UTC)
Under the "Simulation" subsection of the "Software" section it states: "All model based software above." Is that all of the software listed above, or certain members listed above? Aren't all of the names mentioned "model based"? Could someone check on this? Maybe the statement should be: "Any of the software listed above." -- 74.179.120.70 ( talk) 17:57, 13 September 2011 (UTC)
1. Ref 13 links to an empty page.
2. Also in the list of pharmacokinetic metrics, the rate of elimination has been missed out. Could this be included too? Elimination rate constant is different to rate of elimination and including both would prevent confusion for readers. Thanks
Earl Moss (
talk) 13:47, 19 December 2012 (UTC)
Hello Alfie. Thank you very much for reading my comment and trying to act on it.
Regarding No 2: Sure, I can try (btw I'm just a student, no expert). The "Elimination rate constant" (time-1) describes the fraction of drug eliminated from the body in a given time. However the "Rate of elimination" (mass time-1) describes the mass of drug eliminated from the body in a given time. The "Rate of elimination" shares the same units as "Infusion rate". (Example of a sentence using "Rate of elimination": The amount of drug in the body remains constant when the rate of elimination equals the rate of infusion) The example would not make sense if you replaced the phrase "rate of elimination" with "elimination rate constant". I hope that has helped to explain what I meant.
So they are different variables, which leaves the question about whether there is a need to include it in the list. From my lectures, it seems that "Rate of elimination" is often talked about in education and is also used clinically. Added to the fact that some people may confuse the two variables (like me when I first read it), I think that both should be in the table. Feel free to ask for clarification or anything else. I'm happy to discuss it if you disagree. Merry Christmas/Seasons greetings!!
Earl Moss (
talk) 22:17, 24 December 2012 (UTC)
Why does this article lead off with a graph of Michaelis Menten Kinetics? Its a beautiful graph, but is not mentioned until the section on multi-compartment models. I associate the MM curve more with biochemistry than pharmacokinetics, the latter having more to do with drug levels in vivo. So as an introductory figure it kind of misses the point. Additionally, its labeled in Spanish.
This figure should be relabeled in English and moved to the middle portion of the article. The 3rd figure (Farmacocinética_no_lineal.svg) should also be relabeled in English.
I think a better introductory graph would be the IV time vs. concentration curve. (Iv time conc curve.svg) mattelfesso ( talk) 20:58, 29 April 2014 (UTC)
— Preceding unsigned comment added by 70.62.125.212 ( talk) 15:54, 7 August 2014 (UTC)
The last paragraph of the Bioavailability section says "When two drugs have the same bioavailability, they are said to be biological equivalents or bioequivalents. This concept of bioequivalence is important because it is currently used as a yardstick in the authorization of generic drugs in many countries."
This makes it sound like the article is saying bioavailability (BA) and bioequivalence (BE) are the same thing, which is not true. I'm guessing it's trying to say that BA contributes to BE. I don't feel confident enough to edit this sentence (I know the basics, but really just the basics), but I'm hoping someone with more knowledge that me can. Thank you to anyone who can help. — Preceding unsigned comment added by 70.62.125.212 ( talk) 15:58, 7 August 2014 (UTC)
Hello fellow Wikipedians,
I have just modified 3 external links on Pharmacokinetics. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
{{
dead link}}
tag to
http://www.revistanefrologia.com/mostrarfile.asp?ID=1566When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018.
After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than
regular verification using the archive tool instructions below. Editors
have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the
RfC before doing mass systematic removals. This message is updated dynamically through the template {{
source check}}
(last update: 5 June 2024).
Cheers.— InternetArchiveBot ( Report bug) 09:05, 21 September 2017 (UTC)
At [5] there is a need for a section under "Pharmacokinetic data" pertaining to the following:
If anyone is interested in this topic, please aid in the development of its proper titles, details (for all drugs), most importantly, the drug statistics on the population involving their likelihood for a human body to not respond to it. Hopefully, we can approximate dose quantities that lead to these issues in the long term. Twillisjr ( talk) 21:27, 4 September 2018 (UTC)
I tried making diagram, to simplify the description of the relationship between the Kinetics and Dynamics. What do you guys think? Claes Lindhardt ( talk) 20:20, 16 January 2023 (UTC)
I found it confusing which metrics are used where I tried making this diagram where I tried associating the diffrent units with the place where at first glance it sounds like they might belong. But I would really appriacte any help to correct it :) I feel like it is very difficult to keep the overview of all the interplay when everything is only on list form. I can quickly adapt any change suggestions. Thank you in advance Claes Lindhardt ( talk) 20:40, 16 January 2023 (UTC)
References
This
level-4 vital article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||
|
This article contains a translation of Farmacocinética from es.wikipedia. |
Extended content
|
---|
This is an important topic that deserces an article of its own. However, copying the abstradt of a review article verbatim in Wikipedia is against the rules (copyright violation) and not useful, because these docoments are too long and too technical. The editor is welcome to write a short encyclopedic excerpt, taking into account other sources like WHO, NIH etc. Andreas 17:13, 9 January 2006 (UTC) I have been given the assignment of giving a brief lecture at my church on this very topic. I will web-research the topic and write my findings to this article. As a retired, but still licensed registered nurse, I have limited access to hospital medical libraries. I will also make my best effort at including references and links. User:W8IMP 0837, 15 January 2007]] (UTC) Why is this article titled "Pharmacokinetics (section), when there is another article, not a "talk" section devoted to this topic. I would gladly re-title the article as "Drug-drug and drug-herbal interactions", as soon as I have more data, and someone tells me to change the title. User:W8IMP 08:51, 15 January 2007]] (UTC) |
The constant which relates the exponent of decay (k) and half-life is easily determined by first principles from the equation for exponential decay. Mentioning circuit analysis seems totally crazy to me; no pharmacokineticist would know anything about circuits or ever need to. If this is important then I think that the maths only should be mentioned. ben 06:50, 23 May 2006 (UTC)
Shouldn't there be something here about two (or more) compartment models, also non compartmental models? Let me hasten to add, I'm not the person to write it ... Daen 15:22, 25 September 2006 (UTC)
Actually, there are PK model assumptions made for the typical implementation of numerical integration, A.K.A. noncompartmental methods. Those assumptions become important when they are incorrect, which may actually be almost all of the time. Those assumptions commonly, but not always, include (1) that between samples of a monotonically decreasing blood concentration (i.e., a washout model of plasma or whole blood depending on the drug's hydrophilicity and lipophilicity), that the path of concentration is exponential. (2) That one can extrapolate exponentials to earlier times than the first sample time without error. (3) That the last and one or two prior samples can be used to extrapolate the AUC to infinity implying (3a) that the half-life is terminal at that time and (3b) that half-lives only arise from exponential functions. Granted, there are other ways of doing numerical integration, and the selection of extrapolating functions is not trivial. Let us review these assumptions. Ad (1) and (2), there is no evidence to that effect, and early concentration of a renal filtered non metabolized drug has been shown to be more a linear concentration and logarithm of time function than a logarithm of concentration linear time function [1]. Indeed, the former implies an initial zero volume of drug and the later implies an unrealistic instant mixing in an appreciable volume (see below). The dearth of testing on this subject appalls me. Ad (3a), the half-life for the last samples is typically not terminal. Indeed, the terminal function may occur very late in time and may be a power function [2], what the terminal function does not appear to be is an exponential [3], which reference also offers an explanation of drug volumes in time. I welcome comments on this, and have not altered the main text due to a conflict of interest on my part. I need other minds to review this. CarlWesolowski ( talk) 16:08, 23 August 2016 (UTC).
BTW, there are multiple circumstances in which compartmental models are not "the best" at anything. Rather than give a whole bunch of references here regarding the need to correct one compartmental clearances by 15% or so, the superiority of other methods like constant infusion and saturated systems for measuring clearance, adaptive gamma variate fitting for bolus experiment clearances, Michaelis-Menten for saturable receptor clearances and so forth, I just changed the text to be more honest, i.e., from best to most frequently used. Also, there are broken links in the text some of which I have fixed, HELP!!! This isn't my article, so would someone else take care of it, too, please? And, if you don't agree with my (minor) changes, do let's talk, please. CarlWesolowski ( talk) 20:20, 9 February 2017 (UTC)
It may be more useful to refer to Enzyme kinetics. At the very least, there should be a reference to it somewhere in the article. 136.165.191.251 ( talk) 16:07, 27 April 2009 (UTC)
References
Variable volume pharmacokinetic models is now linked to this article. Linking back is a consideration, so is thinking about it. Talk to me. CarlWesolowski ( talk) 14:20, 23 August 2016 (UTC) CarlWesolowski ( talk) 03:44, 9 September 2016 (UTC) No one talked to me. The linking article was an orphan so that linking to it was needed. And for completeness, it should be listed anyway. CarlWesolowski ( talk) 21:53, 17 November 2016 (UTC)
Who "invented" the "Pharmacokinetics"? —Preceding unsigned comment added by 217.86.119.8 ( talk) 21:22, 3 October 2006 (UTC)
References
Would it be useful to have a list of the standard PK parameters, with some brief explanation? Examples: Cmax, Tmax, AUC, etc. —Preceding unsigned comment added by 216.158.41.81 ( talk) 18:35, 27 June 2007 (UTC)
It would be helpful to me! I would definitely read that section carefully. Mlbish ( talk) 21:32, 21 February 2008 (UTC)
References
Several drug properties can often influence the pharmacokinetics of many drugs.
The partition or distribution coefficient (KD) is the ratio of concentrations of a compound in the two phases of a mixture of two immiscible solvents at equilibrium. [1] It can influence the ADME properties (Absorption, Distribution, Metabolism, and Excretion) of the drug. When orally administered drugs are absorbed they must first pass through lipid bilayers in the intestinal epithelium (a process known as transcellular transport). For efficient transport the drug must be hydrophobic enough to partition into the lipid bilayer but not so hydrophobic that once it is in the bilayer it will not partition out again. [2] The partition coefficient is dependent on the hydrophobic or hydrophilic properties of the drug.
References
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
Drug transporters are transmembrane proteins on the surface of cells and are responsible for facilitating or hindering the intracellular and paracellular transport of nutrients and other substances. Some known drug transporters include Breast Cancer Resistance Protein (BCRP, also known as ABCG2) and human intestinal peptide transporter (hPepT1). BCRP is a type of ATP-binding cassette transporter that can decrease the efficacy of chemotherapeutic agents in breast cancer by exporting agents out of the tumor cells, thus making them resistant to chemotherapy. Valacyclovir uses the hPepT1 transporter to increase the intestinal absorption of valacyclovir compared to acyclovir. Drug transporters can increase or decrease the absorption of drugs into the body as well as limit or facilitate the exposure of certain organs.
Perfusion or flow of blood to different organs, affects rate of presentation of drugs to different parts of the body and often affects the pharmacokinetics of many drugs. While the partition coefficient can affect the distribution of drugs from the blood stream to the organs, perfusion affects how fast a drug is presented to the organs. Different organs receive a vast supply of drugs while others receive minor amounts. For example, the kidneys receive vast quantities of blood, especially considering the relatively small size of the kidneys. Adipose tissue, on the other hand, receives a minor supply blood. Organs with a rich blood supply would be presented drug at a higher rate than organs with a lower blood supply.
Biophys ( talk) 01:56, 5 September 2008 (UTC)
Hello. I am a member of WikiProject Pharmacology, a Wikipedia wide project that maintains and improves articles that fall under the scope of pharmacology. Since your article has fallen under our scope, I have placed the correct template(s) on this talk page for verification. Upon review of the article, I'd like to make a few points, as shown:
I'm glad this article could fall within our scope, and I hope to see it grow large! Many thanks! Renaissancee (talk) 02:21, 3 June 2009 (UTC)
This article is quite poor to be in the English version of Wikipedia; I compared it with other versions like the spanish one, and I noticed there is an important lack of information here. An improvement of this article should be done. —Preceding unsigned comment added by 83.44.20.68 ( talk • contribs) 01:20, 20 September 2009 (UTC)
I have added a review of the development of the Plateau Principle in pharmacokinetics and the wide applicability of the mathematical model to other areas in biological sciences. It would be very helpful to obtain an expert review of this new entry. Please provide comments in the talk section of Plateau Principleand delete this section when a review has been done. Many thanks. Jhargrov ( talk) 14:03, 10 October 2009 (UTC)James Hargrove Jhargrov ( talk) 14:03, 10 October 2009 (UTC)
It's been a while since I've dealt with topics in pharmacokinetics. Is "liberation" a new and recognized stage of drug kinetics? If so, please provide citation. -- Bobthefish2 ( talk) 04:53, 7 August 2011 (UTC)
{{
cite book}}
: Unknown parameter |coauthors=
ignored (|author=
suggested) (
help) Some points to note: Liberation is synonymous to drug release (which is by far more commonly used) and is further divided into desintegration and dissolution. There is a wealth of information available. Earlier references on LADME (from the 1970ies) are in German – which is not surprising, since a lot of work in the field at that time was done in German-speaking countries (Germany, Switzerland, Austria; the term pharmacokinetics was translated from Pharmakokinetik – a neologism introduced by
Friedrich Hartmut Dost in 1953). I would keep the statement about LADME in the article as it is – until somebody (te-heh) advances PK to a better shape. ;-)
Alfie
↑↓
© 13:03, 18 August 2011 (UTC)Following copied from User_talk:Boghog#Alpha.2FBeta_phase_of_i.v.:
Hi Boghog, I saw your new section and I think it's well-written. One additional thing that'd be helpful is to include an example chart of concentration vs. time with arrows pointing to the phase where passive diffusion dominates and the phase where elimination dominates (By the way, do you mean elimination as in "excretion" or elimination as in "metabolism" + "excretion"? Some pharmacologists use the term "elimination" in the same way as "excretion"). -- Bobthefish2 ( talk) 18:13, 26 August 2011 (UTC)
End of insert Alfie ↑↓ © 00:07, 1 September 2011 (UTC)
Under the "Simulation" subsection of the "Software" section it states: "All model based software above." Is that all of the software listed above, or certain members listed above? Aren't all of the names mentioned "model based"? Could someone check on this? Maybe the statement should be: "Any of the software listed above." -- 74.179.120.70 ( talk) 17:57, 13 September 2011 (UTC)
1. Ref 13 links to an empty page.
2. Also in the list of pharmacokinetic metrics, the rate of elimination has been missed out. Could this be included too? Elimination rate constant is different to rate of elimination and including both would prevent confusion for readers. Thanks
Earl Moss (
talk) 13:47, 19 December 2012 (UTC)
Hello Alfie. Thank you very much for reading my comment and trying to act on it.
Regarding No 2: Sure, I can try (btw I'm just a student, no expert). The "Elimination rate constant" (time-1) describes the fraction of drug eliminated from the body in a given time. However the "Rate of elimination" (mass time-1) describes the mass of drug eliminated from the body in a given time. The "Rate of elimination" shares the same units as "Infusion rate". (Example of a sentence using "Rate of elimination": The amount of drug in the body remains constant when the rate of elimination equals the rate of infusion) The example would not make sense if you replaced the phrase "rate of elimination" with "elimination rate constant". I hope that has helped to explain what I meant.
So they are different variables, which leaves the question about whether there is a need to include it in the list. From my lectures, it seems that "Rate of elimination" is often talked about in education and is also used clinically. Added to the fact that some people may confuse the two variables (like me when I first read it), I think that both should be in the table. Feel free to ask for clarification or anything else. I'm happy to discuss it if you disagree. Merry Christmas/Seasons greetings!!
Earl Moss (
talk) 22:17, 24 December 2012 (UTC)
Why does this article lead off with a graph of Michaelis Menten Kinetics? Its a beautiful graph, but is not mentioned until the section on multi-compartment models. I associate the MM curve more with biochemistry than pharmacokinetics, the latter having more to do with drug levels in vivo. So as an introductory figure it kind of misses the point. Additionally, its labeled in Spanish.
This figure should be relabeled in English and moved to the middle portion of the article. The 3rd figure (Farmacocinética_no_lineal.svg) should also be relabeled in English.
I think a better introductory graph would be the IV time vs. concentration curve. (Iv time conc curve.svg) mattelfesso ( talk) 20:58, 29 April 2014 (UTC)
— Preceding unsigned comment added by 70.62.125.212 ( talk) 15:54, 7 August 2014 (UTC)
The last paragraph of the Bioavailability section says "When two drugs have the same bioavailability, they are said to be biological equivalents or bioequivalents. This concept of bioequivalence is important because it is currently used as a yardstick in the authorization of generic drugs in many countries."
This makes it sound like the article is saying bioavailability (BA) and bioequivalence (BE) are the same thing, which is not true. I'm guessing it's trying to say that BA contributes to BE. I don't feel confident enough to edit this sentence (I know the basics, but really just the basics), but I'm hoping someone with more knowledge that me can. Thank you to anyone who can help. — Preceding unsigned comment added by 70.62.125.212 ( talk) 15:58, 7 August 2014 (UTC)
Hello fellow Wikipedians,
I have just modified 3 external links on Pharmacokinetics. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
{{
dead link}}
tag to
http://www.revistanefrologia.com/mostrarfile.asp?ID=1566When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018.
After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than
regular verification using the archive tool instructions below. Editors
have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the
RfC before doing mass systematic removals. This message is updated dynamically through the template {{
source check}}
(last update: 5 June 2024).
Cheers.— InternetArchiveBot ( Report bug) 09:05, 21 September 2017 (UTC)
At [5] there is a need for a section under "Pharmacokinetic data" pertaining to the following:
If anyone is interested in this topic, please aid in the development of its proper titles, details (for all drugs), most importantly, the drug statistics on the population involving their likelihood for a human body to not respond to it. Hopefully, we can approximate dose quantities that lead to these issues in the long term. Twillisjr ( talk) 21:27, 4 September 2018 (UTC)
I tried making diagram, to simplify the description of the relationship between the Kinetics and Dynamics. What do you guys think? Claes Lindhardt ( talk) 20:20, 16 January 2023 (UTC)
I found it confusing which metrics are used where I tried making this diagram where I tried associating the diffrent units with the place where at first glance it sounds like they might belong. But I would really appriacte any help to correct it :) I feel like it is very difficult to keep the overview of all the interplay when everything is only on list form. I can quickly adapt any change suggestions. Thank you in advance Claes Lindhardt ( talk) 20:40, 16 January 2023 (UTC)
References